Safety of dupilumab in patients with atopic dermatitis: expert opinion

References

• Gooderham MJ, Hong HC, Eshtiaghi P, et al. Dupilumab: a review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018;78(3):S28–S36.
   PubMed Web of Science ®Google Scholar
• Halling A-S, Loft N, Silverberg JI, et al. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84(1):139–147. .
   PubMed Web of Science ®Google Scholar
• Worm M, Francuzik W, Kraft M, et al. Moderne therapie der atopischen dermatitis: biologika und kleinmolekulare medikamente. J Dtsch Dermatol Ges. 2020;18(10):1085–1093.
   Google Scholar
• Wondemagegnehu, E. and World Health Organization. The Importance of Pharmacovigilance. Safety monitoring of medical products. World Health Organization; 2002. ISBN: 9789241590150. Available from https://books.google.de/books?id=7FEiPAAACAAJ.
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348.
   PubMed Web of Science ®Google Scholar
• Thyssen JP, Toft PB, A-s H-O, et al. Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis. J Am Acad Dermatol. 2017;77(2):280–286.
   PubMed Web of Science ®Google Scholar
• LFM A, van der Schaft J, Spekhorst LS, et al. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-weeks results from the Dutch BioDay registry. J Am Acad Dermatol. 2020 September. DOI:https://doi.org/10.1016/j.jaad.2020.08.127.
   Google Scholar
• Akinlade B, Guttman-Yassky E, Bruin-Weller M, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181(3):459–473.
   PubMed Web of Science ®Google Scholar
• Zirwas MJ, Wulff K, Beckman K. Lifitegrast add-on treatment for dupilumab-induced ocular surface disease (DIOSD): a novel case report. JAAD Case Rep. 2019;5(1):34–36.
   PubMedGoogle Scholar
• Nahum Y, Mimouni M, Livny E, et al. Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment. Br J Ophthalmol. 2019;104(6):776–779.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Ariens L, Thurau S, et al. Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab clinical characteristics and treatment. J Allergy Clin Immunol. 2018;6(5):1778–1780.e1.
   Web of Science ®Google Scholar
• Maudinet A, Law-Koune S, Duretz C, et al. Ocular surface diseases induced by dupilumab in severe atopic dermatitis. Ophthalmol Ther. 2019;8(3):485–490.
   PubMed Web of Science ®Google Scholar
• Barnes AC, Blandford AD, Perry JD. Cicatricial ectropion in a patient treated with dupilumab. Am J Ophthalmol Case Rep. 2017;7:120–122.
   PubMedGoogle Scholar
• Levine RM, Tattersall IW, Gaudio PA, et al. Cicatrizing blepharoconjunctivitis occurring during dupilumab treatment and a proposed algorithm for its management. JAMA Dermatol. 2018;154(12):1485.
   PubMed Web of Science ®Google Scholar
• Liberman P, Shifera AS, Berkenstock M. Dupilumab-associated conjunctivitis in patients with atopic dermatitis. Cornea. 2020;39(6):784–786. .
   PubMed Web of Science ®Google Scholar
• Lee DH, Cohen LM, Yoon MK, et al. Punctal stenosis associated with dupilumab therapy for atopic dermatitis. J Dermatological Treat. 2020 January;1–4. DOI:https://doi.org/10.1080/09546634.2019.1711010
   Google Scholar
• Fargnoli MC, Esposito M, Ferrucci S, et al. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis. J Dermatological Treat. 2019 October;1–7. DOI:https://doi.org/10.1080/09546634.2019.1682503
   Google Scholar
• Fargnoli MC, Esposito M, Ferrucci S, et al. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis. J Dermatological Treat. 2020 July;1–4. DOI:https://doi.org/10.1080/09546634.2020.1773379
   Google Scholar
• Quint T, Brunner PM, Sinz C, et al. Dupilumab for the treatment of atopic dermatitis in an Austrian cohort-real-life data shows rosacea-like folliculitis. J Clin Med. 2020;9(4):1241.
   Web of Science ®Google Scholar
• De Bruin-weller M, Graham NMH, Pirozzi G, et al. Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with demodex and increased interleukin-17 levels?: reply from the authors. Br J Dermatol. 2018;178(5):1220–1221. .
   PubMed Web of Science ®Google Scholar
• Barnett BP, Afshari NA. Dupilumab-associated mucin deficiency (DAMD). Trans Vision Sci Technol. 2020;9(3):29.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–2485.
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496.
   PubMed Web of Science ®Google Scholar
• Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis. JAMA. 2016;315(5):469.
   PubMed Web of Science ®Google Scholar
• Hirano I, Dellon ES, Hamilton JD, et al. Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis. Gastroenterology. 2020;158(1):111–122.e10.
   PubMed Web of Science ®Google Scholar
• Utine CA, Li G, Asbell P, et al. Ocular surface disease associated with dupilumab treatment for atopic diseases. Ocul Surf. 2021;19:151–156.
   PubMed Web of Science ®Google Scholar
• Jun I, Kim B-R, Park SY, et al. Interleukin-4 stimulates lipogenesis in meibocytes by activating the STAT6/PPAR γ signaling pathway. Ocul Surf. 2020;18(4):575–582.
   PubMed Web of Science ®Google Scholar
• Henriksson JT, Coursey TG, Corry DB, et al. IL-13 stimulates proliferation and expression of mucin and immunomodulatory genes in cultured conjunctival goblet cells. Invest Ophthalmol. 2015;56(8):4186.
   Google Scholar
• Dartt DA. Regulation of mucin and fluid secretion by conjunctival epithelial cells. Prog Retin Eye Res. 2002;21(6):555–576.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Blauvelt A, Eichenfield LF, et al. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis. JAMA Dermatol. 2020;156(4):411.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Guttman-Yassky E, Torpet M, et al. Risk of anaphylaxis and conjunctivitis with tralokinumab in atopic dermatitis. SKIN J Cutaneous Med. 2018;2:S63.
   Google Scholar
• Silverberg JI, Toth D, Bieber T, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2020 September. DOI:https://doi.org/10.1111/bjd.19573.
   Web of Science ®Google Scholar
• Faiz S, Giovannelli J, Podevin C, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2019;81(1):143–151.
   PubMed Web of Science ®Google Scholar
• Jang DH, Heo SJ, Jung HJ, et al. Retrospective study of dupilumab treatment for moderate to severe atopic dermatitis in Korea: efficacy and safety of dupilumab in real-world practice. J Clin Med. 2020;9(6):1982.
   Web of Science ®Google Scholar
• Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455–2466.
   PubMed Web of Science ®Google Scholar
• Fleming P, Drucker AM. Risk of infection in patients with atopic dermatitis treated with dupilumab: a meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2018;78(1):62–69.e1.
   PubMed Web of Science ®Google Scholar
• Ou Z, Chen C, Chen A, et al. Adverse events of dupilumab in adults with moderate-to-severe atopic dermatitis: a meta-analysis. Int Immunopharmacol. 2018;54:303–310.
   PubMed Web of Science ®Google Scholar
• Lernia VD, Casanova DM, Simonetti V. Dupilumab kann die abheilung von molluscum contagiosum bei patienten mit atopischer dermatitis erleichtern. J Dtsch Dermatol Ges. 2020;18(9):1016–1018.
   Google Scholar
• Storan ER, Woolf RT, Smith CH, et al. Clearance of molluscum contagiosum virus infection in patients with atopic eczema treated with dupilumab. Br J Dermatol. 2019;181(2):385–386.
   PubMed Web of Science ®Google Scholar
• Ferrucci S, Tavecchio S, Veraldi S, et al. Transitory dissemination of molluscum contagiosum in a patient treated with dupilumab for atopic dermatitis. Acta Dermatol Venereologica. 2020;100(14):adv00207.
   PubMed Web of Science ®Google Scholar
• Sevray M, Dupré D, Misery L, et al. Hair regrowth and dissemination of molluscum contagiosum: two unexpected effects with dupilumab. J Eur Acad Dermatol Venereol. 2019;33:8.
   Web of Science ®Google Scholar
• Heibel HD, Hendricks AJ, Foshee JP, et al. Rosacea associated with dupilumab therapy. J Dermatological Treat. 2019;32(1):114–116.
   PubMed Web of Science ®Google Scholar
• Zhu GA, Chen JK, Chiou A, et al. Assessment of the development of new regional dermatoses in patients treated for atopic dermatitis with dupilumab. JAMA Dermatol. 2019;155(7):850.
   PubMed Web of Science ®Google Scholar
• Espinosa ML, Nguyen MT, Aguirre AS, et al. Progression of cutaneous t-cell lymphoma after dupilumab: case review of 7 patients. J Am Acad Dermatol. 2020;83(1):197–199.
   PubMed Web of Science ®Google Scholar
• Tran J, Morris L, Vu A, et al. Development of sézary syndrome following the administration of dupilumab. Dermatol Online J. 2020;15(26):13030/qt1m67z8sb.
   Google Scholar
• Hollins LC, Wirth P, Jr GJF, et al. Long-standing dermatitis treated with dupilumab with subsequent progression to cutaneous t-cell lymphoma. Cutis. 2020;106(2). DOI:https://doi.org/10.12788/cutis.0074
   Google Scholar
• Miyashiro D, Vivarelli AG, Gonçalves F, et al. Progression of mycosis fungoides after treatment with dupilumab: a case report. Dermatol Ther. 2020 July. DOI:https://doi.org/10.1111/dth.13880.
   Google Scholar
• Chiba T, Nagai T, Osada S, et al. Diagnosis of mycosis fungoides following administration of dupilumab for misdiagnosed atopic dermatitis. Acta Dermatol Venereologica. 2019;99(9):818–819.
   PubMed Web of Science ®Google Scholar
• Umemoto N, Demitsu T, Otaki K, et al. Dupilumab therapy in sézary syndrome misdiagnosed as atopic dermatitis: a case report. J Dermatol. 2020 July. DOI:https://doi.org/10.1111/1346-8138.15501.
   Google Scholar
• Geskin LJ, Viragova S, Stolz DB, et al. Interleukin-13 is overexpressed in cutaneous t-cell lymphoma cells and regulates their proliferation. Blood J Am Soc Hematol. 2015;125(18):2798–2805.
   Google Scholar
• Saulite I, Hoetzenecker W, Weidinger S, et al. Sézary syndrome and atopic dermatitis: comparison of immunological aspects and targets. Biomed Res Int. 2016;2016:1–15.
   Web of Science ®Google Scholar
• Napolitano M, Scalvenzi M, Fabbrocini G, et al. Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: a case series. Dermatol Ther. 2019;32(6):e13142.
   PubMed Web of Science ®Google Scholar
• Stout M, Guitart J, Tan T, et al. Psoriasis-like dermatitis developing in a patient with atopic dermatitis treated with dupilumab. Dermatitis. 2019;30(6):376–378.
   PubMed Web of Science ®Google Scholar
• Varma A, Levitt J. Dupilumab-induced phenotype switching from atopic dermatitis to psoriasis. JAAD Case Rep. 2020;6(3):217–218.
   PubMedGoogle Scholar
• Ferrucci S, Tavecchio S, Berti E, et al. Acute onset of psoriasis in a patient with atopic dermatitis treated with dupilumab. Clin Exp Dermatol. 2020;45(5):625–626.
   PubMed Web of Science ®Google Scholar
• Tracey EH, Elston C, Feasel P, et al. Erythrodermic presentation of psoriasis in a patient treated with dupilumab. JAAD Case Rep. 2018;4(7):708–710.
   PubMedGoogle Scholar
• DeGrazia TM, Raji K, Alshamekh S, et al. Psoriatic plaques after initiation of dupilumab therapy. Dermatitis. 2020;31(4):e36–e37.
   PubMed Web of Science ®Google Scholar
• Wijs LEM, Nguyen NT, Kunkeler ACM, et al. Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series. Br J Dermatol. 2019;183(4):745–749.
   PubMed Web of Science ®Google Scholar
• de Beer FSA, Bakker DS, Haeck I, et al. Dupilumab facial redness: positive effect of itraconazole. JAAD Case Rep. 2019;5(10):888–891.
   PubMedGoogle Scholar
• Napolitano M, Caiazzo G, Fabbrocini G, et al. Increased expression of interleukin-23A in lesional skin of patients with atopic dermatitis with psoriasiform reaction during dupilumab treatment. Br J Dermatol. 2020;184(2):341–343.
   PubMed Web of Science ®Google Scholar
• Bosma AL, de Wijs LEM, Hof MH, et al. Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry. J Am Acad Dermatol. 2020;83(5):1375–1384.
   PubMed Web of Science ®Google Scholar
• Wijs LEM, Waa JD, Jong PHP, et al. Acute arthritis and arthralgia as an adverse drug reaction to dupilumab. Clin Exp Dermatol. 2019;45(2):262–263.
   PubMed Web of Science ®Google Scholar
• Willsmore ZN, Woolf RT, Hughes C, et al. Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series. Br J Dermatol. 2019;181(5):1068–1070.
   PubMed Web of Science ®Google Scholar
• Johansson EK, Ivert LU, Bradley B, et al. Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study. BMC Dermatol. 2020;20(1). DOI:https://doi.org/10.1186/s12895-020-00103-0
   Google Scholar
• Barroso-Garcı́a B, Rial M, Molina A, et al. Alopecia areata in severe atopic dermatitis treated with dupilumab. J Invest Aller Clin Immun. 2018;28(6):420–421. .
   PubMed Web of Science ®Google Scholar
• Salgüero-Fernández I, De Domingo MAG, Suarez D, et al. Dermatitis and alopecia in a patient treated with dupilumab: a new adverse effect? Clin Exp Dermatol. 2018 December. DOI:https://doi.org/10.1111/ced.13858.
   Google Scholar
• Mitchell K, Levitt J. Alopecia areata after dupilumab for atopic dermatitis. JAAD Case Rep. 2018;4(2):143–144.
   PubMedGoogle Scholar
• Flanagan K, Sperling L, Lin J. Drug-induced alopecia after dupilumab therapy. JAAD Case Rep. 2019;5(1):54–56.
   PubMedGoogle Scholar
• Uchida H, Kamata M, Watanabe A, et al. Dupilumab improved alopecia areata in a patient with atopic dermatitis: a case report. Acta Dermatol Venereologica. 2019;99(7):675–676.
   PubMed Web of Science ®Google Scholar
• Harada K, Irisawa R, Ito T, et al. The effectiveness of dupilumab in patients with alopecia areata who have atopic dermatitis: a case series of seven patients. Br J Dermatol. 2020;183(2):396–397.
   PubMed Web of Science ®Google Scholar
• Darrigade A-S, Legrand A, Andreu N, et al. Dual efficacy of dupilumab in a patient with concomitant atopic dermatitis and alopecia areata. Br J Dermatol. 2018 Jun. DOI:https://doi.org/10.1111/bjd.16711.
   Google Scholar
• Penzi LR, Yasuda M, Manatis-Lornell A, et al. Hair regrowth in a patient with long-standing alopecia totalis and atopic dermatitis treated with dupilumab. JAMA Dermatol. 2018;154(11):1358.
   PubMed Web of Science ®Google Scholar
• Gruenstein D, Malik K, Levitt J. Full scalp hair regrowth in a 4-year-old girl with alopecia areata and atopic dermatitis treated with dupilumab. JAAD Case Rep. 2020;6(12):1286–1287.
   PubMedGoogle Scholar
• Andersen YMF, Egeberg A, Gislason GH, et al. Autoimmune diseases in adults with atopic dermatitis. J Am Acad Dermatol. 2017;76(2):274–280.e1.
   PubMed Web of Science ®Google Scholar
• Maloney NJ, Worswick S, Cheng K. Development of alopecia in patients treated with dupilumab. Dermatol Ther. 2019;32:3.
   Web of Science ®Google Scholar
• Treudler R, Delaroque N, Puder M, et al. Dupilumab-induced serum sickness-like reaction: an unusual adverse effect in a patient with atopic eczema. J Eur Acad Dermatol Venereol. 2020;35:1.
   Web of Science ®Google Scholar
• Narantsatsral D, Junko T, Hideyuki I, et al. Painless thyroiditis in a dupilumab-treated patient. Endocrinol Diabetes Metab Case Rep. 2020;2020. DOI:https://doi.org/10.1530/edm-20-0030.
   Google Scholar
• Rowane M, Valencia R, Schend J, et al. Something to sweat about: two cases of dupilumab-induced hyperhidrosis and bromhidrosis. Aller Rhinol. 2020;11:215265672092770.
   Web of Science ®Google Scholar
• Ludriksone L, Elsner P, Schliemann S. Acquired hypersensitivity to dupilumab: first case report. J Eur Acad Dermatol Venereol. 2019;33(12). DOI:https://doi.org/10.1111/jdv.15807
   Google Scholar
• Gusenbauer M. Google scholar to overshadow them all? Comparing the sizes of 12 academic search engines and bibliographic databases. Scientometrics. 2018;118(1):177–214.
   Web of Science ®Google Scholar
• Agache I, Song Y, Posso M, et al. Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI biologicals guidelines. Allergy. 2020;76(1):45–58. .
   PubMed Web of Science ®Google Scholar